AIMS:To evaluate the effect of the Accu-Chek® SmartGuide Predict app Night Low Predict (NLP) feature use on nocturnal hypoglycemia in people with diabetes in a real-world setting. METHODS:This retrospective analysis used deidentified, aggregated data from Predict app users. Outcomes included hypoglycemic events of any severity (glucose < 70 mg/dL), level 2 (L2) events (glucose < 54 mg/dL), hyperglycemic events (glucose > 180 mg/dL), time below 70 mg/dL (TB70), time below 54 mg/dL (TB54), and time above 180 mg/dL (TAR). Users without nocturnal hypoglycemic events were excluded. Nights when predictions were received were compared with nights when predictions were not generated. RESULTS:Data from 249 people (aged 20-84 years) showed NLP use was associated with 20.0 % lower odds of hypoglycemic events of any severity occurring in a given night and 31.2 % lower odds of any TB70 occurring. Data from 159 people showed NLP use was associated with 31.0 % lower odds of L2 events occurring and 39.2 % lower odds of any TB54 occurring. Hyperglycemic events and TAR were not affected by NLP use. CONCLUSION:NLP use is associated with lower odds of nocturnal hypoglycemia in people with diabetes without raising odds of hyperglycemia, offering valuable self-management support.
To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose monitoring (CGM) for the first time in this population. This was a Phase 3b, 12-week, single-treatment study in adults with T2D on basal-bolus multiple daily injection (MDI) therapy using basal insulin glargine U-100 along with a rapid-acting insulin analog. Following a 4-week baseline period, 176 participants were newly treated with prandial URLi. Participants used unblinded CGM (Freestyle Libre). Primary endpoint was time in range (TIR) (70–180 mg/dl) during the daytime period at Week 12 compared to baseline with gated secondary endpoints of HbA1c change from baseline and 24-h TIR (70–180 mg/dl). Improved glycemic control was observed at Week 12 versus baseline including mean daytime TIR (change from baseline [Δ] 3.8
Background: Severe hypoglycemic episodes are life-threatening events demanding rapid administration of glucagon by a caregiver or bystander. The glucagon analog dasiglucagon is stable in aqueous formulation and therefore suitable for delivery in a ready-to-use autoinjector, potentially increasing speed and ease of use compared with standard glucagon emergency kits (GEKs).Methods: In an open label, randomized, crossover, comparative device handling study, trained caregivers and untrained bystanders administered the dasiglucagon autoinjector or Eli Lilly GEK to manikins in a simulated emergency hypoglycemia situation.Results: In total, 54 participants were randomized (18 patient-caregiver pairs and 18 bystanders). Overall, 94% of trained caregivers were able to administer the dasiglucagon autoinjector successfully within 15 min, compared with 56% for the GEK (P < 0.05). A greater proportion of trained caregivers and untrained bystanders successfully prepared and administered the dasiglucagon autoinjector within 2 min compared with the GEK (P < 0.005 and P < 0.05, respectively). Time to successful completion was also significantly faster with the dasiglucagon autoinjector than with the GEK (P < 0.005 for both groups). Most study participants preferred the dasiglucagon autoinjector over the GEK (94%, P < 0.001) and rated it as easier (90%, P < 0.001) and less stressful to use (94%, P < 0.001) than the GEK.Conclusion: Dasiglucagon autoinjector was more rapidly and reliably administered, and users reported greater ease of use and usage satisfaction than with the GEK. Thus, dasiglucagon autoinjector has the potential to improve speed and ease of treatment in severe hypoglycemic events, providing a better usage experience for rescuing individuals and enabling faster recovery for patients.
